ONO-4059

Known as: BTK Inhibitor ONO-4059, Bruton's Tyrosine Kinase Inhibitor ONO-4059 
An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
0120132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION Over the last few years, several new synthetic drugs, particularly Bruton's tyrosine kinase (BTK… (More)
Is this relevant?
Review
2015
Review
2015
INTRODUCTION Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs… (More)
Is this relevant?
2014
2014
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more… (More)
Is this relevant?
Review
2014
Review
2014
BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the… (More)
Is this relevant?
2014
2014
Treatment for chronic lymphocytic leukemia (CLL) is undergoing a dramatic shift: Targeted drugs are replacing the often… (More)
Is this relevant?
2014
2014
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more… (More)
Is this relevant?
Review
2013
Review
2013
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?